On this page
What makes a comparative BA or bioequivalence report reviewable?
Identify the exact test and reference products, application context, study conduct, analytical evidence and prespecified comparison. Report the estimate, uncertainty and applicable decision criterion together. Explain exclusions and changes without extending a favorable result into a claim of approval, therapeutic equivalence or an untested product bridge.
Before you begin
Comparative BA/BE reporting. ANDA PK-endpoint studies, NDA formulation bridges and other product contexts require different scientific and regulatory decisions.
What you will prepare: A comparative report with resolved product identity, prespecified analysis, transparent deviations and qualified conclusions.
Resolve what is being compared and why
Identify the application pathway and the role of the comparison: an ANDA demonstration, an NDA formulation bridge, a manufacturing-change assessment or another supported use. Record the test product, reference product, strength, dosage form, batch and administration conditions. For an ANDA, the responsible team should resolve the reference listed drug and reference-standard roles from current FDA records rather than treating the names as interchangeable.
FDA's ANDA PK-endpoint guidance became final in May 2026. Check it alongside the applicable product-specific guidance and relevant harmonized guidance for the actual product. A result obtained with one formulation type or endpoint does not establish the method for every other product.
Explain the design and the analysis decisions together
Gather the protocol, amendments, statistical plan, randomization/treatment records, analytical evidence and approved results. Describe the design, periods or groups, dosing, sampling and evaluability rules. Account for actual participants and samples through to the reported comparisons. Make the timing and rationale of analysis changes visible.
For each endpoint show the estimand or comparison being evaluated, analysis population, method, estimate, uncertainty and applicable decision criterion with its source. Do not paste a familiar acceptance range into a study with an unconfirmed design, analyte or product-specific approach. Where the required interpretation remains unresolved, present the findings and assign the decision to the qualified reviewer.
Connect analytical reliability to the conclusion
Match sample identifiers and assay versions to the clinical dataset. Review documented repeat analysis, reintegration, failed runs and stability excursions for their impact on the final concentrations. M10 distinguishes general analytical reporting from additional comparative BA/BE documentation; have the analytical owner reconcile the applicable package rather than assuming the routine clinical-pharmacology report contains everything.
Fictional exercise: the statistical report compares test batch T-02 with reference batch R-04, while the bioanalytical report labels its reference samples R-03. Stop the identity handoff. Reconcile source dosing and sample records before deciding whether this is a label error or a different treatment. Renaming a PDF cannot resolve the underlying evidence mismatch.
State the outcome without expanding the claim
Report whether the prespecified comparison met the applicable criterion and discuss deviations, exclusions and uncertainty that affect interpretation. Distinguish a favorable endpoint result from the broader application decision; a report alone does not establish therapeutic equivalence, approval or acceptance of a waiver.
Maintain one authoritative report package in 5.3.1.2, with the appropriate cross-references from the study listing and biopharmaceutics summary. If the tested and proposed commercial products differ, identify the separate evidence connecting them. Unexplained differences stay visible in the review record.
Trace the equivalence statement through five records
Use one comparison record for each endpoint and condition that supports the report's conclusion.
| Record | Confirm | Escalate when |
|---|---|---|
| Product identity | Test and reference codes match dosing records | Labels differ across clinical and laboratory records |
| Analysis population | Inclusion and exclusion rules match the output | A participant disappears without a disposition |
| Analytical input | Final accepted concentrations and method versions | Corrected values have not reached the analysis |
| Statistical result | Estimate, uncertainty, method and criterion source | Only a favorable point estimate is quoted |
| Claim | Product and condition match the evaluated comparison | The statement extends to an untested strength or formulation |
Review exercise: the synopsis states that the comparison succeeded, while one report table uses a superseded analysis population. Have the analyst identify the authoritative outputs and assess affected conclusions. Updating the synopsis alone leaves the evidence chain unresolved.
Keep analytical investigations connected through the human bioanalytical report. Carry the qualified result into the biopharmaceutics summary, with any separate evidence required for the proposed commercial product.
Your preparation checklist
0/4 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Is the 2021 ANDA PK-endpoint BE draft still the current FDA version?
The FDA guidance inspected for this article is the May 2026 final, which supersedes the August 2021 draft. Check the final document, applicable harmonized guidance and product-specific recommendations for the actual submission; its ANDA context should not be assumed for every formulation bridge.
Are the reference listed drug and reference standard the same concept?
No. FDA distinguishes the product relied on for the ANDA from the designated product used for the in-vivo comparison. They may be the same product, but the roles are different. Resolve both from current FDA records and document the product actually used.
Does meeting a BE criterion mean the application is approved?
No. The study conclusion concerns the evaluated comparison under its actual conditions and applicable criteria. The broader application decision involves additional evidence and requirements. Report the scientific outcome accurately without converting it into an approval or therapeutic-equivalence determination.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
FDA M4E(R2): The CTD: Efficacy ↗July 2017, Revision 1, final. Module 5, printed pp.56–64. Organization guidance, not a list of studies required for every application. Reopened September 22, 2026.
Guidance
FDA M10: Bioanalytical Method Validation and Study Sample Analysis ↗November 2022 final. Scope and section VIII, including Table 1 documentation distinctions. Reopened September 22, 2026.
Guidance
FDA BE Studies With PK Endpoints for Drugs Submitted Under an ANDA ↗May 2026 final; supersedes the August 2021 draft. ANDA-specific scope and current final status reopened September 22, 2026.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 5.3.1.2. A heading identifies placement, not mandatory applicability.